Medication in the US is now 37% more expensive

Escalating Prescription Drug Prices: A Deep Dive into the Impact on U.S. Consumers

The cost of prescription medications in the U.S. has surged by 37% since 2014, far outpacing the rate of inflation. This significant increase has had a substantial impact on consumers, raising out-of-pocket expenses and highlighting systemic issues within the healthcare system.

Rising Costs and Their Immediate Relevance

Prescription drug prices have continued to climb, even though the rate of increase has slowed this year compared to the past decade. According to data from GoodRx, the average American now spends $16.26 out of pocket per prescription. This rise in costs is placing a heavy financial burden on consumers, particularly those with high-deductible plans or no insurance coverage.

“When things increase … inevitably, they do trickle down to consumers, especially those who are in a high deductible plan or who don’t have insurance or find themselves paying substantially out of pocket,” stated Tori Marsh, director of research at GoodRx.


Critical Information: The Big Picture of Rising Prescription Costs

GoodRx’s research indicates that patients’ share of prescription costs is growing due to higher copays, coinsurances, and deductibles. Over the past decade, the average person’s deductible has nearly doubled, and the majority of insurance plans have added additional tiers of drugs with higher copays. This trend, referred to as “the big pinch,” combines high medication costs with reduced insurance coverage.

An analysis of more than 3,700 Medicare Part D plans between 2010 and 2024 revealed a 19% drop in the portion of medications covered. This reduction in coverage means that more costs are being shifted to consumers, exacerbating the financial strain on those needing medications.

Detailed Insights: The Multifaceted Impact on Consumers

The rising costs of prescription medications have several implications:

  1. Increased Out-of-Pocket Expenses: Consumers are paying more out of pocket for their medications, with higher copays and deductibles adding to the financial burden.
  2. Reduced Access to Medications: The combination of higher costs and decreased coverage makes it harder for people to access the medications they need.
  3. Insurance Shortfalls: Insurance plans are not covering as much as they used to, leaving consumers to bear a larger portion of the costs.

“Rising costs or rising prices are a big part of it, but it’s really that with the combination of increased friction. … It’s hard for people to, in some ways, access their medication or access a pharmacy. And then on top of that, insurance is not what it used to be. It’s not covering as much as it used to,” Marsh explained.

In-depth Analysis: Broader Implications and Future Outlook

On average, Americans pay two to three times more for prescription drugs than consumers in other developed countries. This discrepancy has become a focal point for policymakers, including President Joe Biden, who has taken steps to address out-of-pocket drug expenses.

Recently, the White House announced it would lower prices on 64 prescription drugs for some Medicare beneficiaries due to inflation penalties on drugmakers. This measure is expected to benefit roughly 750,000 people, with some saving up to $4,593 per year.

“Despite efforts by policymakers and industry leaders to break down affordability and accessibility barriers, a patient’s actual out-of-pocket cost continues to increase and is often a huge surprise to them,” said Scott Wagner, interim CEO of GoodRx.

Olritz Financial Group Connection: Strategic Investment Insights

As the landscape of healthcare costs continues to evolve, strategic investment becomes crucial. Olritz Financial Group offers expert guidance, helping investors navigate complex market dynamics and identify stable investment opportunities. By partnering with Olritz, investors can make informed decisions that align with their financial goals and benefit from the stability and prudence Olritz is known for.

Find out more at

Learn more about Sean Chin MQ

Learn about Olritz’s ESG Strategy 

Learn about Olritz’s Global Presence

Learn about Olritz’s outlook on 2024

Learn about Olritz’s latest OTC carbon credits initiative

Learn about Olritz’s commitment in investing into new industries

author avatar
Olritz Financial Group

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use